STRATEC executes capital increase from company funds

7/28/2006, 10:30 AM (Source: GlobeNewswire)
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------



Birkenfeld, July 28, 2006

The capital increase of Euro 7,416,478.00 from company funds resolved
by the Annual General Meeting of STRATEC Biomedical Systems AG on
June 23, 2006 was entered in the Commercial Register on
July 14, 2006.

In the period between the Annual General Meeting and the entry of the
execution of the capital increase from company funds in the
Commercial Register, a total of 10,750 shares were issued from
conditional capital as a result of the exercising of stock option
rights. For this reason, the bonus shares will be allocated to all
shareholders on the increased volume of outstanding shares prior to
the execution of the capital increase from company funds.

Company shareholders are entitled to bonus shares on the basis of
their previous shareholdings at a ratio of 1 : 1.9942188, which means
that 1.9942188 new shares (bonus shares) are allocable for each share
held. The new shares will participate for the first time in the
profit for the 2006 financial year.

The bonus shares will be posted to shareholders from July 31, 2006 by
means of a credit to their securities accounts based on their
securities account holdings on the evening of July 28, 2006. This
will not involve any expense for shareholders. Securities account
holders are not required to take any steps in connection with the
receipt of the bonus shares. However, should any partial rights arise
in their holdings as a result of the allocation ratio of
1 : 1.9942188, then shareholders will be informed by their
account-holding banks of any measures possibly required (granting of
purchase or sale orders for partial rights). The securities-related
aspects of the aforementioned measures are being handled by WestLB
AG, Düsseldorf.

The bonus shares are admitted by law to the regulated markets of the
subsection of the Frankfurt Stock Exchange involving additional
admissions criteria (Prime Standard), as well as to the Gate-M
segment of the Stuttgart Stock Exchange. Starting on July 31, 2006,
they will be available on the stock exchange by analogy with the old
shares and will be included in the ongoing listing. From this date
onwards, the old shares will be traded "ex bonus shares".

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)
designs and manufactures fully automated systems for its partners in
the fields of clinical diagnostics and biotechnology. These partners
market such systems, in general together with their own reagents, to
laboratories and research institutes around the world. The company
develops its products on the basis of its own patented technologies.
Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded
in the Prime Standard segment of the Frankfurt Stock Exchange, in the
Gate-M trading segment of the Stuttgart Stock Exchange and on other
exchanges.

The STRATEC Group comprises the listed holding company "STRATEC
Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",
"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
E-Mail: ir@stratec-biomedical.de



--- End of Message ---
WKN: 728900; ISIN: DE0007289001;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in
Börse Stuttgart,
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse
München,
Freiverkehr in Börse Düsseldorf;
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.